Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Aug 15;143A(16):1827-34.
doi: 10.1002/ajmg.a.31853.

Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype

Affiliations
Case Reports

Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype

Neora Alterman et al. Am J Med Genet A. .

Abstract

Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by progressive neurodegeneration, immunodeficiency, susceptibility to cancer, genomic instability, and sensitivity to ionizing radiation. A-T is caused by mutations that eliminate or inactivate the nuclear protein kinase ATM, the chief activator of the cellular response to double strand breaks (DSBs) in the DNA. Mild A-T is usually caused by ATM mutations that leave residual amounts of active ATM. We studied two siblings with mild A-T, as defined by clinical examination and a quantitative A-T neurological index. Surprisingly, no ATM was detected in the patients' cells, and sequence analysis revealed that they were homozygous for a truncating ATM mutation (5653delA) that is expected to lead to the classical, severe neurological presentation. Moreover, the cellular phenotype of these patients was indistinguishable from that of classical A-T: all the tested parameters of the DSB response were severely defective as in typical A-T. This analysis shows that the severity of the neurological component of A-T is determined not only by ATM mutations but also by other influences yet to be found.

PubMed Disclaimer

Similar articles

Cited by

  • Multidisciplinary Management of Ataxia Telangiectasia: Current Perspectives.
    McGrath-Morrow SA, Rothblum-Oviatt CC, Wright J, Schlechter H, Lefton-Greif MA, Natale VA, Crawford TO, Lederman HM. McGrath-Morrow SA, et al. J Multidiscip Healthc. 2021 Jun 28;14:1637-1644. doi: 10.2147/JMDH.S295486. eCollection 2021. J Multidiscip Healthc. 2021. PMID: 34234451 Free PMC article. Review.
  • Individual Cytokines Modulate the Neurological Symptoms of ATM Deficiency in a Region Specific Manner.
    Hui CW, Herrup K. Hui CW, et al. eNeuro. 2015 Aug 18;2(4):ENEURO.0032-15.2015. doi: 10.1523/ENEURO.0032-15.2015. eCollection 2015 Jul-Aug. eNeuro. 2015. PMID: 26465009 Free PMC article.
  • An update on inherited ataxias.
    Schmitz-Hübsch T, Klockgether T. Schmitz-Hübsch T, et al. Curr Neurol Neurosci Rep. 2008 Jul;8(4):310-9. doi: 10.1007/s11910-008-0048-4. Curr Neurol Neurosci Rep. 2008. PMID: 18590615 Review.
  • Autosomal recessive adult onset ataxia.
    Dragašević-Mišković N, Stanković I, Milovanović A, Kostić VS. Dragašević-Mišković N, et al. J Neurol. 2022 Jan;269(1):504-533. doi: 10.1007/s00415-021-10763-8. Epub 2021 Sep 9. J Neurol. 2022. PMID: 34499204
  • Ataxia-telangiectasia in Latin America: clinical features, immunodeficiency, and mortality in a multicenter study.
    Pereira RA, Dantas EO, Loekmanwidjaja J, Mazzucchelli JTL, Aranda CS, Serrano MEG, De La Cruz Córdoba EA, Bezrodnik L, Moreira I, Ferreira JFS, Dantas VM, Sales VSF, Fernandez CC, Vilela MMS, Motta IP, Franco JL, Arango JCO, Álvarez-Álvarez JA, Cardozo LRR, Orellana JC, Condino-Neto A, Kokron CM, Barros MT, Regairaz L, Cabanillas D, Suarez CLN, Rosario NA, Chong-Neto HJ, Takano OA, Nadaf MISV, Moraes LSL, Tavares FS, Rabelo F, Pino J, Calderon WC, Mendoza-Quispe D, Goudouris ES, Patiño V, Montenegro C, Souza MS, Branco AB, Forte WCN, Carvalho FAA, Segundo G, Cheik MFA, Roxo-Junior P, Peres M, Oliveira AM, Neto ACP, Ortega-López MC, Lozano A, Lozano NA, Nieto LH, Grumach AS, Costa DC, Antunes NMN, Nudelman V, Pereira CTM, Martinez MDM, Quiroz FJR, Cardona AA, Nuñez-Nuñez ME, Rodriguez JA, Cuellar CM, Vijoditz G, Bichuetti-Silva DC, Prando CCM, Amantéa SL, Costa-Carvalho BT. Pereira RA, et al. Immunol Res. 2024 Aug;72(4):864-873. doi: 10.1007/s12026-024-09494-5. Epub 2024 Jun 4. Immunol Res. 2024. PMID: 38834764

Publication types

MeSH terms

Substances